We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Axela Licenses Beckman's Universal Linker Capture Technology

By Labmedica staff writers
Posted on 20 Dec 2006
Axela Biosensors Inc. More...
(Toronto, Canada), and Beckman Coulter Inc. (Fullerton, CA, USA), have announced the signing of a nonexclusive licensing agreement that gives Axela rights to Beckman Coulter's patented A2 universal linker capture technology. The terms of the license were not disclosed. Axela will incorporate the technology into its dotLab Sensors, which will give scientists the unique ability to create user-defined multiplex biomarker panels.

Combining A2 universal linkers with the recently launched dotLab System allows scientists to create custom multiplex protein assays without the need for specialized pipetting or spotting techniques. Axela plans to use the technology in conjunction with its dotLab sensors to allow users to define their own biomarker panels and to use either the Axela library of pre-conjugated antibodies or their own reagents with universal linkers.

"The innovative Universal Linker approach will allow users to tag their own antibodies or draw from a library of existing markers to build combined assays with micromolar to picomolar sensitivity requirements,” explained Rocky Ganske, CEO of Axela Biosensors.

"Coupled with the dotLab System, this self-addressing DNA approach gives the translational scientist a simple and flexible method to perform multiplexed immunoassays, and has the potential to significantly transform the speed in which putative biomarkers can be validated.”

Axela Biosensors is commercializing products that accelerate the validation of protein biomarkers from discovery into routine clinical practice. The company has developed a proprietary breakthrough technology called diffractive optics technology (dot), which enables the real-time detection and quantitation of protein-binding events in complex media. Axela developed this technology into the dotLabSystem, a commercially available benchtop laboratory system that delivers simple, affordable, yet highly sensitive protein based assays. To leverage the opportunities that dot creates, Axela has assembled a management team with extensive experience in diagnostic and research product development and commercialization.

Beckman Coulter, Inc. manufactures biomedical testing instrument systems, tests, and supplies that simplify and automate laboratory processes.



Related Links:
Axela Biosensors
Beckman Coulter

Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.